Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Do you offer adjuvant radiation therapy for sacral chordoma s/p gross total resection with close margins <0.5 cm?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · The Ohio State University - James Cancer Hospital and Solove Research Institute

Yes to adjuvant RT, but doses of 50-60 Gy have no benefit in chordoma. 70 Gy is required even with R0 margins. See Konieczkowski et al., PMID 32147017 for a full discussion of the literature.

How do you manage a cervical cancer that needs interstitial brachytherapy with prolonged thrombocytopenia after concurrent chemoRT?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Although infrequent, we have done pre op plt transfusion to make brachytherapy feasible and to avoid prolonging the total duration.

Is it essential to wait one week after loading dose of erbitux to start RT for head and neck cancer?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · NYC Health + Hospitals

I would start RT if it means you're going to risk delaying RT start window. Another question is, why are you giving Erbitux for post-op treatment? Can you use another agent?

How do you do approach treatment of a recurrent gliosarcoma?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Florida International University

Primary gliosarcoma remains a challenging clinical conundrum. There are no curative therapies and little to no high level evidence to guide decision-making. Most approaches have followed patterns similar to those used for recurrent glioblastoma. The outcomes are usually poor. However, it does help, ...

Does microscopic ENE warrant post-mastectomy radiotherapy if all other factors are low risk?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Allegheny Health Network, Pittsburgh

With respect to ENE, I first look at axillary surgery. If the patient has SLN+ and microscopic ENE, I do typically offer PMRT even with other low-risk factors. While the IBCSG trial evaluates micrometastases, it's important to remember 90% received lumpectomy, and therefore, most received whole brea...

How do you approach treatment for a patient with uveal melanoma who is not a candidate for plaque brachytherapy

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan Kettering Cancer Center

If plaque brachytherapy is not possible, we consider proton beam therapy to a dose of 50 Gy/5 fractions. Enucleation of the eye is the surgical alternative.

Is tumor deposit (N1c) alone an indication for adjuvant chemoRT for rectal cancer that did not receive neoadjuvant therapy?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan-Kettering Cancer Center

Some patients such as this were undoubtedly included in the early rectal cancer trials [GITSG and Mayo North Central (NCCTG)] that established the role of post-operative chemoradiation for stage II and III rectal cancer. However, accrual numbers were too small for stratification of TN subsets and it...

Do you recommend prophylactic ureteral stenting in patients who have recently completed SBRT to a region in close proximity to the ureter prior to the potential development of fibrosis?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Physician Health Partners

No, just F/U MRI.

Do you consider high para-aortic nodes above the renal vessels to be locally advanced or metastatic in cervical cancer?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Karmanos Cancer Institute - McLaren Proton Therapy Center

It sounds like you are asking how aggressively to treat patients with para-aortic nodal spread. My limit for "para-aortic" or "regional LAD" is usually anything below the diaphragm. I generally think of and treat these patients as advanced stage III.I would also advocate for definitively treating ce...

Is it appropriate to use hypofractionation to treat breast cancer when the patient is receiving concurrent TDM-1 (Kadcyla)?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

We have been using it routinely with no increased acute side effects and are looking at our data systemically.